Multidisciplinary Insights and Strategies for Patients Treated With PI3K and AKT Inhibitors to Prevent Hyperglycemia

Program Description

Hyperglycemia is a common adverse effect of targeted PI3K and AKT inhibitors in breast cancer and requires a multidisciplinary approach to management. At this intersection of oncology and endocrinology, effective care requires the expertise of oncologists to manage the primary cancer treatment and pharmacists to navigate the nuanced drug interactions and select appropriate antihyperglycemic agents that do not compromise anticancer efficacy. In this panel discussion, experts will provide a concise review of risk factors and prevention strategies, providing a foundation for a deeper discussion on implementation and actionable, real-world solutions within care teams. The core of this program will be dedicated to pharmacist-led interventions, where panelists will share their experiences and successes in leveraging team-based care to prevent treatment-induced hyperglycemia. The discussion will cover crucial topics such as patient monitoring, the nuances of selecting appropriate antihyperglycemic therapies, and strategies for navigating the challenges of multidisciplinary management. By highlighting successful models, best practices, and protocols for monitoring and management, this panel will equip oncology pharmacists to take a leadership role in developing and implementing institutional guidelines, ultimately improving patient outcomes and continuity of care for those receiving PI3K and AKT inhibitor therapies.

Target Audience: Oncology Pharmacist

Type of Activity: Application
Release date: November 7, 2025
Expiration date: November 7, 2026
Learner level: Intermediate
Time to complete activity: 1.0 hour
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Examine pharmacist-led interventions for hyperglycemia management, emphasizing clinical opportunities in patient monitoring, therapy selection, and interdisciplinary collaboration
• Determine potential solutions to challenges in selecting antihyperglycemic therapies for patients treated with PI3K/AKT inhibitors
• Investigate pharmacist-integrated models and protocols for hyperglycemia management, including contributions to clinical guidelines and best practice implementation

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hours (0.10 CEU) under the ACPE universal activity number 0290-0000-25-361-H05-P. The activity is available for CE credit through November 7, 2025.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, view the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

Taylor Monson, PharmD, BCPS, BCOP, has the following relevant financial relationships with ineligible companies to disclose:

Advisory Boards: AstraZeneca, Eli Lilly

Megan May, PharmD, BCOP, has the following relevant financial relationships with ineligible companies to disclose:

Speakers Bureau: Amgen, AstraZenca

Jodi Taraba, PharmD, MSc, BCOP, has the following relevant financial relationships with ineligible companies to disclose:

Grant/Research Support: Eli Lilly

Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Daphne Davis, PharmD, BCOP; Victoria Chirdo; Susan Pordon; Brianna Winters; and Chloe Taccetta have no relevant financial relationships with ineligible companies to disclose.

Pharmacy Times® Editorial Staff— Aislinn Antrim

Any relevant financial relationships listed for these individuals have been mitigated.

At least one anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with ineligible companies to disclose.

Educational Disclaimer

CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
ceinfo@pharmacytimes.com
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms